← Back to Screener
Mineralys Therapeutics, Inc. Common Stock (MLYS)
Price$30.56
Favorite Metrics
Price vs S&P 500 (26W)-22.83%
Price vs S&P 500 (4W)21.46%
Market Capitalization$2.51B
All Metrics
Book Value / Share (Quarterly)$7.93
P/TBV (Annual)2.42x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.75
Price vs S&P 500 (YTD)-18.82%
EPS (TTM)$-2.38
10-Day Avg Trading Volume1.37M
EPS Excl Extra (TTM)$-2.38
EPS (Annual)$-2.29
ROI (Annual)-23.91%
Cash / Share (Quarterly)$8.05
ROA (Last FY)-23.37%
EBITD / Share (TTM)$-2.52
ROE (5Y Avg)-98.88%
Cash Flow / Share (Annual)$-1.75
P/B Ratio3.88x
P/B Ratio (Quarterly)4.44x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-27.37x
ROA (TTM)-31.68%
EPS Incl Extra (Annual)$-2.29
Current Ratio (Annual)43.76x
Quick Ratio (Quarterly)43.45x
3-Month Avg Trading Volume1.32M
52-Week Price Return118.53%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.42
52-Week High$47.65
EPS Excl Extra (Annual)$-2.29
26-Week Price Return-18.85%
Quick Ratio (Annual)43.45x
13-Week Price Return-7.76%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)43.76x
Enterprise Value$2,333.671
Revenue / Employee (Annual)$0
Cash / Share (Annual)$8.05
3-Month Return Std Dev65.89%
Net Income / Employee (TTM)$-2
ROE (Last FY)-23.91%
EPS Basic Excl Extra (Annual)$-2.29
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.38
ROI (TTM)-32.94%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.87
Price vs S&P 500 (52W)88.70%
Year-to-Date Return-16.18%
5-Day Price Return11.96%
EPS Normalized (Annual)$-2.29
ROA (5Y Avg)-67.76%
Month-to-Date Return12.29%
Cash Flow / Share (TTM)$-1.21
EBITD / Share (Annual)$-2.52
ROI (5Y Avg)-98.88%
EPS Basic Excl Extra (TTM)$-2.38
P/TBV (Quarterly)0.98x
P/B Ratio (Annual)4.44x
Book Value / Share (Annual)$7.93
Price vs S&P 500 (13W)-8.45%
Beta0.66x
Revenue / Share (TTM)$0.00
ROE (TTM)-32.94%
52-Week Low$12.59
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MLYSMineralys Therapeutics, Inc. Common Stock | — | — | — | — | $30.56 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, a selective aldosterone synthase inhibitor for treatment-resistant hypertension. The orally administered drug targets abnormally elevated aldosterone levels in patients who have not responded to multiple existing antihypertensive therapies.